⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 32 in last 7 days 🍎 Food: 1 in last 7 days 🧸 Products: 0 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 44 minutes ago ⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 32 in last 7 days 🍎 Food: 1 in last 7 days 🧸 Products: 0 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 44 minutes ago
🛡️ EUSW
🇬🇧
💊

DuoResp Spiromax

budesonide;formoterol
Pulmonary Disease, Chronic Obstructive;Asthma
✅ Authorised
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.

What it's used for

Asthma DuoResp Spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting ?? adrenoceptor agonist) is appropriate: in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting ?? adrenoceptor agonists. or in patients already adequately controlled on both inhaled corticosteroids and long-acting ?? adrenoceptor agonists. COPDDuoResp Spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV?) <70% predicted normal (post bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.

⚠️ Patient safety

No

⚠️ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.